The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Time Perspective: Retrospective and Prospective
Study Type
OBSERVATIONAL
Enrollment
150
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
Time frame: At 3 months post treatment change
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
Time frame: At 6 months post treatment change
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
Time frame: At 12 months post treatment change
Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
Time frame: Baseline
Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
Time frame: 3 months after start of treatment
Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
Time frame: 6 months after start of treatment
Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
Time frame: 12 months after start of treatment
Best response rates achieved by patients if no CCyR
Time frame: Baseline
Best response rates achieved by patients if no CCyR
Time frame: 3 months after start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Best response rates achieved by patients if no CCyR
Time frame: 6 months after start of treatment
Best response rates achieved by patients if no CCyR
Time frame: 12 months after start of treatment